Delaware is set to receive $68.9 million out of a $17.3 billion settlement from drug makers Teva and Allergan and pharmacies CVS and Walgreens.
The money will be spread out over the next 15 years, according to a press release by the Delaware Department of Justice.
The defendants will start releasing funds to a national administrator later this summer, with money expected to go to state and local governments by the end of 2023.
The settlement requires Teva’s opioid business to provide stringent injunctive relief to, among other things, prevent all opioid marketing and prevent drug misuse.
Allergan is required to stop selling opioids for the next 10 years.
CVS and Walgreens agreed to monitor, report and share data about suspicious activity related to opioid prescriptions.
Last year, Walmart agreed to a $3.1 billion settlement, with $11.8 million going to Delaware.
Related Story: Walmart agrees to $3.1B opioid settlement, $11.8M goes to DE
Money from this settlement, along with others, will be deposited into the Prescription Opioid Settlement Distribution Fund created by Senate Bill 166, which will be used to undo the harm caused by opioids.
All told, around $250 million will be put into the fund from different settlements.
Multiple states and attorneys general were involved in the suit.
Delaware Attorney General Kathy Jennings said in the press release that the settlement will help Delaware deal with the opioid crisis.
“Delaware continues to experience one of the nation’s highest fatal overdose rates, and these settlements will be a significant boost to our continued fight against the opioid epidemic,” Jennings said. “Both the dollars won, and the stipulations requiring new systems to be put in place prevent drug misuse will have an enormous impact on the landscape of this crisis and save countless lives.”
Share this Post